Science Translational Medicine | Epigenetic Dysregulation of Metabolic Programs Drives Cell Plasticity in Liposarcoma

This study reveals the epigenetic inactivation mechanism of the PPARG2 and IGF1 signaling axis in liposarcoma, providing a novel experimental framework for tumor therapeutic strategies based on differentiation blockade. It particularly suggests that antibody-drug conjugates (ADCs) targeting IGF1R may have clinical translational potential.

 

Literature Overview

This paper, 'Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity,' published in Science Translational Medicine, systematically investigates the molecular basis of cellular plasticity across liposarcoma (LPS) subtypes. By integrating single-nucleus multi-omics and spatial transcriptomic analyses, the research team uncovers epigenetic silencing of the IGF1 signaling pathway in dedifferentiated liposarcoma (DDLPS) and its regulatory role on PPARG2 expression, offering a high-resolution map for understanding LPS pathogenesis.

Background Knowledge

1. The clinical challenge addressed in this study: DDLPS is associated with high recurrence and metastatic risk. Current therapies lack effective targeted options, leaving patients reliant on non-specific chemotherapy with poor prognosis. Existing treatments fail to reverse the dedifferentiated state, highlighting an urgent need for precision interventions grounded in molecular mechanisms.
2. Current bottlenecks in IGF1R research: Although IGF1R is overexpressed in various cancers, clinical outcomes with monoclonal antibodies have been limited, possibly due to signaling redundancy or downstream blockade. This study reveals that IGF1R is compensatorily upregulated in DDLPS due to upstream IGF1 loss, suggesting its potential as a synthetic lethal target.
3. Research rationale: The authors focused on differentiation differences between LPS subtypes, using snRNA-seq and snATAC-seq to systematically analyze transcriptional and chromatin accessibility disparities between WDLPS and DDLPS. They identified hierarchical dysregulation of the IGF1-IGF1R-PPARG2 axis, providing a mechanistic foundation for subsequent targeted interventions.

 

 

Research Methods and Experiments

The authors performed single-nucleus multi-omics sequencing (snRNA-seq + snATAC-seq) on 23 human samples, including normal adipose tissue, WDLPS, and DDLPS, ensuring large cells such as adipocytes were not missed. Spatial transcriptomics and immunofluorescence validation enabled spatial mapping of molecular features. In vitro, IGF1-induced differentiation was tested in DDLPS cell lines, and functional necessity was confirmed by PPARG2 overexpression. Additionally, an IGF1R-ADC was evaluated for its selective cytotoxic effects on tumor cells.

Key Conclusions and Perspectives

• IGF1 and PPARG expression are significantly higher in WDLPS than in DDLPS, and IGF1 chromatin accessibility is closed in DDLPS — indicating that IGF1 signaling loss is an epigenetic hallmark of DDLPS, guiding subsequent mechanistic validation
• IGF1 signaling loss correlates with patient survival; DDLPS patients retaining IGF1 expression have better outcomes — supporting IGF1 as both a prognostic biomarker and a potential therapeutic target
• DDLPS cells fail to undergo adipogenesis in response to IGF1, and basal PPARG2 expression is extremely low — revealing that PPARG2 deficiency is the core defect underlying differentiation blockade, impacting the design of cell fate reprogramming strategies
• Restoring PPARG2 expression alone is sufficient to restart adipogenic programs without additional stimuli — confirming PPARG2 as a molecular switch for LPS cell state, providing a theoretical basis for gene therapy or epigenetic activation
• IGF1R is compensatorily overexpressed in DDLPS and localized to the cell membrane — supporting its rationale as an ADC target and advancing targeted drug development
• IGF1R-ADC shows selective cytotoxicity against DDLPS cell lines with high IGF1R expression — providing preclinical evidence for non-chemotherapy strategies and influencing drug screening pipelines

Research Significance and Prospects

From a drug development perspective, this study reveals the therapeutic potential of IGF1R-ADC in DDLPS, particularly for patients with low IGF1 and high IGF1R expression, suggesting future stratified therapies based on this dual biomarker.

In clinical monitoring, IGF1 expression levels could serve as a prognostic marker to assist in risk stratification and treatment decisions.

For disease modeling, the study emphasizes the need to develop animal models that recapitulate PPARG2 loss and IGF1R upregulation, such as humanized target mice or conditional knockout models, to more accurately simulate the DDLPS microenvironment.

 

 

Conclusion

This study systematically dissects the molecular mechanisms underlying cellular plasticity across liposarcoma subtypes from the perspectives of epigenetics and metabolic reprogramming. Through integrated multi-omics analysis, it reveals that silencing of IGF1 signaling leads to PPARG2 loss, thereby blocking the differentiation pathway. This finding not only deepens our understanding of liposarcoma biology but also provides a strategy to identify synthetic lethal targets downstream of 'undruggable' transcription factors. Restoring PPARG2 reprograms tumor cell states, while IGF1R-ADC leverages compensatory mechanisms for selective killing—both pointing to a new paradigm of differentiation-directed therapy. This work establishes a mechanistic foundation for precision medicine in liposarcoma, advancing the transition from traditional chemotherapy to combined targeted and differentiation therapies, with the potential to significantly improve patient outcomes.

 

Erica M Pimenta, Amanda E Garza, Sabrina Y Camp, George D Demetri, and Eliezer M Van Allen. Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity. Science translational medicine.